158 related articles for article (PubMed ID: 25866685)
1. Nelarabine associated myotoxicity and rhabdomyolysis.
Haider M; Rizvi SA; Kasi PM
Case Rep Hematol; 2015; 2015():825670. PubMed ID: 25866685
[TBL] [Abstract][Full Text] [Related]
2. Nelarabine: a novel purine antimetabolite antineoplastic agent.
Buie LW; Epstein SS; Lindley CM
Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
[TBL] [Abstract][Full Text] [Related]
3. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
[TBL] [Abstract][Full Text] [Related]
4. Nelarabine-induced rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia: a case report.
Utsumi A; Goto Y; Suzuki T; Imai C; Matsui S; Sakaida E; Ishii I
J Pharm Health Care Sci; 2022 Jun; 8(1):17. PubMed ID: 35690835
[TBL] [Abstract][Full Text] [Related]
5. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Massie T; Sridhara R; McGuinn WD; Abraham S; Booth BP; Goheer MA; Morse D; Chen XH; Chidambaram N; Kenna L; Gobburu JV; Justice R; Pazdur R
Clin Cancer Res; 2006 Sep; 12(18):5329-35. PubMed ID: 17000665
[TBL] [Abstract][Full Text] [Related]
6. Nelarabine-associated reversible Guillain-Barré-like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma.
Lalayanni C; Baldoumi E; Papayiannopoulos S; Tziola K; Saloum R; Anagnostopoulos A
Curr Probl Cancer; 2017; 41(2):138-143. PubMed ID: 28169005
[TBL] [Abstract][Full Text] [Related]
7. Nelarabine in the treatment of refractory T-cell malignancies.
Roecker AM; Stockert A; Kisor DF
Clin Med Insights Oncol; 2010 Dec; 4():133-41. PubMed ID: 21151585
[TBL] [Abstract][Full Text] [Related]
8. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
DeAngelo DJ
Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
[TBL] [Abstract][Full Text] [Related]
9. Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.
Reilly KM; Kisor DF
Onco Targets Ther; 2009 Feb; 2():219-28. PubMed ID: 20616909
[TBL] [Abstract][Full Text] [Related]
10. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.
Kadia TM; Gandhi V
Expert Rev Hematol; 2017 Jan; 10(1):1-8. PubMed ID: 27869523
[TBL] [Abstract][Full Text] [Related]
11. Clofarabine and nelarabine: two new purine nucleoside analogs.
Gandhi V; Plunkett W
Curr Opin Oncol; 2006 Nov; 18(6):584-90. PubMed ID: 16988579
[TBL] [Abstract][Full Text] [Related]
12. Nelarabine: efficacy in the treatment of clinical malignancies.
Roecker AM; Allison JC; Kisor DF
Future Oncol; 2006 Aug; 2(4):441-8. PubMed ID: 16922610
[TBL] [Abstract][Full Text] [Related]
13. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
Candoni A; Lazzarotto D; Petruzzellis G
Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
Boddu PC; Senapati J; Ravandi-Kashani F; Jabbour EJ; Jain N; Ayres M; Chen Y; Keating MJ; Kantarjian HM; Gandhi V; Kadia TM
Cancer; 2023 Feb; 129(4):580-589. PubMed ID: 36448227
[TBL] [Abstract][Full Text] [Related]
15. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
Shimony S; DeAngelo DJ; Luskin MR
Blood Adv; 2024 Jan; 8(1):23-36. PubMed ID: 37389830
[TBL] [Abstract][Full Text] [Related]
16. Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
Cooper TM
Ther Clin Risk Manag; 2007 Dec; 3(6):1135-41. PubMed ID: 18516261
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL.
Horibe K; Takimoto T; Yokozawa T; Makimoto A; Kobayashi Y; Ogawa C; Ohno R; Koh N; Katsura K; Tobinai K
Rinsho Ketsueki; 2011 Jun; 52(6):406-15. PubMed ID: 21737993
[TBL] [Abstract][Full Text] [Related]
18. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI
Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
[TBL] [Abstract][Full Text] [Related]
20. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.
Czuczman MS; Porcu P; Johnson J; Niedzwiecki D; Kelly M; Hsi ED; Cook JR; Canellos G; Cheson BD;
Leuk Lymphoma; 2007 Jan; 48(1):97-103. PubMed ID: 17325852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
